|
Flavay™
protects the blood platelets without an
increased risk of
bleeding
and other common side effects of aspirin.
When we are under stress, our adrenaline flows and causes our blood vessels
to constrict, increasing blood pressure, and blood platelets are activated—prepared
to clump together to form a clot. This "fight or flight response"
is appropriate in short-term dangerous situations. The blood platelets
are prepared for an injury to more quickly form a blood clot and more
efficiently prevent blood loss.
Chronic stress causes constant constriction of blood vessels and continuously
"sticky" blood platelets, always prepared to form a clot. These
are classic risk factors for heart disease and stroke. When blood vessels
are constricted there is less area for the blood to flow through and atherosclerotic
plaque may further reduce the space for blood flow. If some blood platelets
stick together and form a clot, the vessel may be completely clogged and
surrounding tissue is deprived of oxygen and nutrients. This is how a
heart attacks and strokes develop.
Research shows that Flavay™ improves nitric oxide levels produced
by cells that line the arteries. Nitric oxide controls the muscles surrounding
the blood vessels and causes them to relax. At the same time, nitric oxide
causes blood platelets to return to their normal, smooth condition.
Flavay™ inhibits platelet aggregation by inhibiting the enzymes
thromboxane A2, 5-lipoxygenase and other clotting compounds. The good
news is that Flavay™ protects the blood platelets without an increased
risk of bleeding and other common side effects of aspirin.
Aspirin is widely prescribed by doctors to prevent heart attacks because
of its ability to inhibit platelet aggregation by inhibiting the enzyme
cyclooxygenase. However, Flavay™ works differently. Flavay™
supports the body's own production of nitric oxide—helping the body
to produce adequate levels and thereby causing the blood platelets to
return to their normal, smooth condition.
Flavay™ and the Nitric Oxide Connection
Nitric oxide is a colorless gas produced by different cells in the body
that, depending on the situation, can be very good or very
bad. Nitric oxide plays several important roles in the body:
- Nitric oxide is an important signaling molecule that turns genes
on and off.
- By controlling the muscular tone of blood vessels, nitric oxide
regulates the circulation and normalizes blood flow.
- Nitric oxide modulates communication between brain cells and is
instrumental in helping us concentrate and learn new information,
and also in maintaining memory.
- When produced by immune cells, nitric oxide fights infection, kills
tumor cells and promotes wound healing.
- Nitric oxide is essential for perceiving pleasure and pain, and
it helps translate sexual excitement into penile erections.
- Nitric oxide aids in digestion of food by helping to control gastric
movements.
But nitric oxide can be very destructive under other circumstances:
- Nitric oxide restricts blood flow.
- When produced in excess by immune cells, nitric oxide can trigger
chronic inflammation, which can cause arthritis, colitis, inflammatory
bowel disease and possibly cancer.
- Nitric oxide promotes production of more free radicals.
- In the brain, nitric oxide can hamper mental function and cause
memory loss and brain aging.
The real trouble starts when nitric oxide encounters the superoxide free
radical and becomes peroxynitrate, which destroys antioxidants like
glutathione,
vitamin E and common flavonoids, and damages proteins in the body. The
good news is that Flavay™ scavenges peroxynitrate and has a remarkable
modulatory effect on nitric oxide—helping to maintain optimal levels
in the body and neutralizing this free radical where it does harm.
"Radical Scavenger Effect"
of Flavay™
Protected by U.S. Patent No. 4,698,360
Patented and licensed in France for therapeutic uses, the U.S. Government
granted Dr. Masquelier a patent on October 6, 1987 which allows his proanthocyanidins
complex, now sold as Flavay™, to be used as an antioxidant here in
the United States.
|
"[A]
method for preventing and fighting the harmful
biological effects of free radicals in the
organism of warm blooded animals and more especially human
beings, namely cerebral involution, hypoxia following
atherosclerosis, cardiac or cerebral infarction,
tumour promotion, inflammation, ischaemia,
alterations of the synovial liquid, collagen
degradation, among others. The method consists in
administering to said animals and especially to human
beings an amount, efficient against said effects, of a
plant extract with a proanthocyanidins content which has a
radical scavenger effect"—Dr. Jack
Masquelier, U.S. Patent No. 4,698,360.
|
Flavay™
is the product—used in the actual experiments—by
which Dr. Jack Masquelier established and patented the "Radical
Scavenger Effect."
|
Flavay™ is the product—used in the actual experiments—by
which Dr. Jack Masquelier established and patented the "radical scavenger
effect."
Flavay™ has been sold world-wide for cardiovascular health and extensively
tested in humans for more than 50 years. The vascular protective activity
of Flavay™ has been established by many significant studies, demonstrating
several important ways in which Flavay™ may mitigate the risk of
heart attack and stroke. [More...]
 CLICK
HERE FOR AN INDEPENDENT LAB REPORT
Statements made herein have not been
evaluated by the Food and Drug Administration. These products are not intended
to diagnose, treat, cure or prevent any disease.
|
REFERENCES:
Top 
|
Masquelier, J.
Plant extract with a proanthocyanidins content as a therapeutic agent
having radical scavenging effect and use thereof. U.S. Patent No.
4,698,360, 1987.
Masquelier, J. A lifetime devoted to OPC and Pycnogenols. Alfa Omega
Editrice, Pub., 1996.
Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega
Editrice,
Publishers, 1995.
Lombard, J., Germano, C. The brain wellness plan: breakthrough medical,
nutritional and immune-boosting therapies to prevent and treat:
depression, Alzheimer's disease, chronic fatigue syndrome, attention
deficit disorder, multiple sclerosis, Parkinson's disease, Lou Gehrig's
disease. Kensington Pub. Corp., 1998.
Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats
Publishing, Inc., 1997.
Packer, L., et al. The antioxidant miracle: your complete plan. John
Wiley & Sons, Inc., 1999.
Packer, L., et al. Antioxidant food supplements in human health.
Academic Press, 1999.
Lincoln, J., Hoyle, C.H.V., Burnstock, G., Nitric oxide in health and
disease. Cambridge University Press, 1997.
Moncada, S., Nistico, G., Bagetta, G., Higgs, E.A. Nitric oxide and the
cell. Princeton University Press, 1998.
Facino, R.M., et al. Free radical scavenging action and anti-enzyme
activities of procyanidines from vitis vinifera. A mechanism for their
capillary protective action. Arzneimittelforschung, 44: 592-601, 1994.
Passwater, R.A. The antioxidants: the nutrients that guard your body.
Keats Publishing, Inc., 1985.
Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants.
Keats Publishing, Inc., 1995.
Facino RM, et al. Free radical scavenging action and anti-enzyme
activities of procyanidines from Vitis vinifera. A mechanism for their
capillary protective action. Arzneimittelforschung, 44: 592-601, 1994.
Kuttan R, et al. Collagen treated with catechin becomes resistant to the
action of mammalian collagenase. Experientia, 37: 221-223, 1981.
Masquelier, J., et al. Stabilization du collagene par les oligomeres
procyanidoliques. Acta Therapeutica, 7:101-105, 1981.
Masquelier, J. Aspects pharmacologiques nouveaux de certains
flavonoides.
A Vie Medical 12:1969.
Laparra, J., et al. Etude pharmaco-cinetique des oligomers
procyandoliques totaux du raisin. Acta Therapeutica, 4, 1978.
Laparra, J., et al. Etude pharmacocinetique des oligomeres
flavonoliques.
Plantes med et phyto, Tome XI, pp. 133-142, 1977.
Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action des
oligomeres procyanidoliques sur des cellules mesenchymateuses en
culture. Ii l’attachment des fibres elastiques aux cellules. (Study of
the effect of procyanidolic oligomers on mesenchymal cells in culture.
Ii attachment of elastic fibers to the cells.) Pat Biol, (30)6:601-7,
1990.
Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular and
crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin
[(2r,3s,+r)-(+)-3,3’, 4.4’, 5.7’-Hexahydroxyflavan] dihydrate, and
comparison of its heterocyclic ring conformation in solution and the
solid state. Journal of the Chemical Society; Perkin Transactions I
1985. pp. 1413-17.
Masquelier, J. Proanthocyanidins et radicaux libres. 1985.
Uchida, S., et al. Condensed tannins scavenge active oxygen free
radicals. Med Sci Res, (15) 1987. pp. 831-832.
Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and
b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990.
pp. 2499-2504.
Da Silva, R., et. al. Radical scavenger capacity of different
procyanidins from grape seeds. Presented at a symposium, “Free
radicals in biotechnology and medicine.” Royal Society Of Chemistry,
London January 1990, pp. 79-80.
Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der
prostagladinsynthetase durch flavonoide und phenolderivate im vergleich
nit deren 02 radikalfangereigenschaften” Arch Pharm, (Weinheim) 313
(1980) pp. 330-337.
Flesch M., et al., Effects of red and white wine on
endothelium-dependent vasorelaxation of rat aorta and human coronary
arteries. Am J Physiol 1998;275:1183-94.
Fitzpatrick, D.F., Fleming R.C., Bing B, Maggi DA, O'Malley RM.
Isolation and characterization of endothelium-dependent vasorelaxing
compounds from grape seeds. J Agr & Food Chem In press.
Fitzpatrick, D.F., Maggi D, Bing B, Coffey RG. Vasorelaxation,
endothelium, and wine. BioFactors 1997;6:455-459.
Fitzpatrick, D.F., Hirschfield SL, Ricci T, Jantzen P, Coffey RG.
Endothelium-dependent vasorelaxation caused by various plant extracts. J
Cardiovasc Pharmacol 1995;26:90-95.
Fitzpatrick, D.F., Hirschfield SL, Coffey RG. Endothelium-dependent
vasorelaxing activity of wine and other grape products. Amer J Physiol
1993;265:H774-H778.
Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with
catechin becomes resistant to the action of mammalian collagenase.
Experientia, 37: 221-223, 1981.
Masquelier, J. Procyanidolic oligomers. J Parums Cosm
Arom, 95: 89-97,
1990.
Tixier, J.M., et al. Evidence by in vivo and in vitro studies that
binding of pycnogenols to elastin affects its rate of degradation by
elastases. Biochem Pharmacol, 33: 3933-3939, 1984.
Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985.
Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers
extracted from ‘vitus vinifera l.’ in the rat. European Journal of
Drug Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30.
Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging
activity of proanthocyanidolic oligomers encapsulated in glycospheres:
an in vivo and in vitro study. Cosmetology Department & S Biovectors,
Ramonville St. Agne France. pp. 1-9.
Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i converting
enzyme by flavanolic compounds: in vitro and in vivo studies. Planta
Medica, May 26, 1986. pp. 12-15.
Barbier, A., et al. Activite angioprotectrice des oligomeres
procyanidolques chez l’animal-oedenme de la patte. Sanofi Res Toul
Cedex Fr, pp31-40.
Barbier, A., et al. Activite angioprotectrice des oligomeres
procyanidolques chez l’animal-activite aniagoniste vis-a-vis des
mediateurs de l’inflamation. Sanofi Res Toul Cedex Fr, pp. 31-40.
Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance
capillaire,
spontanement ou artificiellement diminuee par l’action d’une
substance capillaro-toxique chez des personnes agees--action benefique
d’un agnet actif sur la micro-circulation: l’Endotelon. Inform.
Therapeut. 1980. pp. 302-305.
Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude d’un
microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7, 1990.
Lagrue, G., Olivier-Martin, F., Grillot, A. “Etude des effets des
oligomeres du procyanidol sur las resistance capillaire dand
l’hypertension arterielle et certaines nephropathies.” Sen. Hosp.
Paris 18-25 Septembre, 1981.
Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur
peripherique, l’Endotelon. Actualite Therapeutique Gaz. Med. de France
(87)22:2919-24, 1980.
Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice de
fragilite capillaire dan une population specifique: les sujets
cirrhotiques. Gaz. Med. de France, (90)24 1983.
Sarrat, L. Abord therapeutique des troubles fonctionnels des membres
inferieurs par un microangioprotecteur l’Endotelon. Bordeaux Med,
11:685-8, 1981.
Delacroix, P. Etude en double aveugle de l’Endotelon dans
l’insuffisance veineuse chronique. Therapeutique, la Revue de
Medicine, (27-28) Sept. 1981. pp. 1793-1802.
Thebaut, J.F, Thebaut, P., Vin, F. Etude de l’Endotelon dand les
manifestations fonctionnelles de l’insuffisance veineuse
peripherique-resultats d’une etude en double aveugle portant sur 92
patients.” Gazette Medicale, (92)1, 1985. pp. 96-100.
Wegrowski, J., Robert, A.M., Maczar, M. The effect of procyanidolic
oligomers on the composition of normal and hypercholesterolemic rabbit
aortas. Biochem. Pharmacol, (33)21. 1984. pp. 3491-3497.
Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and
arachidonate metabolism in platelets by procyanidins. Prostagland
Leukotri Essent Fatty Acids, 38:181-8, 1989.
Masquelier, J. Pycnogenols: recent advances in the therapeutical
activity of procyanidins. Supplement of Planta Medica, Journal of
Medicinal Plant Research and Journal of Natural Products, July 1980 pp.
243-256.
Henning, B., et al. Lipid peroxidation and endothelial cell injury:
implications in atherosclerosis. Free Rad Path & Med, (4)1988 pp.
99-106.
Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.”
pp. 88-93.
Gazave, J.M. “Notions recentes sur les capillaires”
unpub. bulletin
from the Laboratoire De Physiologie Patholigie pp. 26-29.
Ruf, J.C. Wine and polyphenols related to platelet aggregation and
atherothrombosis. Office International Vigne et du Vin, Nutrition and
Health Unit, Paris France; Drugs under Experimental and Clinical
Research (Switz.) 25/2-3 (125-131), 1999.
Blaszo, G. Gabor, M. Oedema-inhibiting effect of
procyanidin. Acta
Physiologica Academiae Scientiarum Hungaricae, Tomus 56(2):235-240,
1980.
Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase.
Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en
gynecologie.
Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
Henriet, J.P “Une Etude Exemplaire Pour Un Phlebotrope: l’etude
EIVE.’ Unpub., pp. 77-83.
Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres
procyanidoliques dans la paroi des capillaires sanguins du poumon
decobaye. Acta Therapeutica (8) 1982. pp. 223-237.
Kuttan, R., Donnelly, P., Di Ferrante, N. “Collagen treated with (+)
-catechin
becomes resistant to the action of mammalian collagenase.” Laboratory
of Connective Tissue Research, Dept. of Biochem. Baylor Col. of Med.,
Houston TX. 28, May, 1980.
Gendre, P., Laparra, J., Barraud, E. “Effect protecteur des oligomeres
procyanidoliques sur le lathyrisme experimental chez le rat.” Ann.
Pharm. Francaises, (43)1, 1985 pp. 61-73.
Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal
circulation. Study of the effect of procyanidolic oligomer (Endotelon).
Jn. Fr. Opthalmol, (11)5:453-460, 1988.
Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and
dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol
Fr, 88(2):173-4, 177-9, 1988.
Proto, F. et al. Electrophysical study of vitis vinifera procyanoside
oligomers effects on retinal function in myopic subjects. Ann Ott Clin
Ocul, 114:85-93, 1988.
Saracco, J.B., Estachy, G.M. Etude d l’Endotelon en
opthalmologie. Gaz
Med de France, 88:2035-2038, 1981.
Scharrer, A., Ober, M. Anthocyanosides in the treatment of
retinopathies. Klin Monatsbl Augenheilkd, 178:386-389, 1981.
Corbe, C., et al. Microangiopathy of the retina. J. Fr.
Opthalmol,
11:453, 1988.
Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et
O.P.C. Bordeaux Medicale, (16)11. pp. 1467-74, 1978.
Soyeux, A. et al. Endotelon. Diabetic retinopathy and
hemorheology. Bull
Soc Ophtalmol Fr. 87(12):1441-4, 1987.
Fromantin, M. “Les oligomeres procyanidoliques dans le traitement de
la fragilite capillaire et de la retinopathie chez les diabetiques. A
propos de 26 cas.” Med Int, 16(11):432-434, Nov. 1981.
Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques:
Endotelon, dans la retinopathie diabetique (a propos de 30
observations). Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
Baruch, J. Effect of Endotelon in postoperative edema. Results of a
double-blind study versus placebo in 32 female patients. Ann Chir Plast
Esthet 29(4):393-5, 1984.
Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism
in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981.
Gabor, M. Pharmacologic effects of flavonoids on blood vessels.
Angiologica, 9:355-374, 1972.
Havsteen, B. Flavonoids, a class of natural products of high
pharmacological potency. Biochem Pharmacol, 32:1141-48, 1983.
Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer, H.J.
Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger., 1977.
Masquelier, J. Action protectrice du vin sur l’ulcere
gastrique. Resultats, p. 61.
Amella, M., et al. Inhibition of mast cell histamine release by
flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985.
Shaw, R. How [Australian] PycnoGenol [MASQUELIER’s®] Helps Sports
People.
Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums Cosmet
Arom 95:89-97, 1990.
Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques
(Endotelon) dans le traitement des lymphoedemes post-therepeutiques de
members superieurs. Symposium Satellite, Congres International
d’Angiologie, Toulouse, France, 4-7 Oct. 1989.
|
|
